Rik J. Deitsch, President and CEO of Nutra Pharma, Interviews with The Wall Street Transcript

• On 2:03 pm EST, Monday November 2, 2009

67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. Included in this 76 page feature is an interview with Rik Deitsch of Nutra Pharma. The full interview is available via The Wall Street Transcript Online.

Topics covered: Company Background - Product Pipeline - Growth Opportunities - Distribution Agreements - Management - Investor Milestones

Companies include: Nutra Pharma

In the following brief excerpt Rik Deitsch discusses the situation at Nutra Pharma.

RIK J. DEITSCH has been the President, Chief Executive Officer and a Director of Nutra Pharma since Nov. 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting, Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from cone snail venom, cobra venom and gila monster venom. Mr. Deitsch holds both a B.S. in chemistry and an M.S. in biochemistry from Florida Atlantic University, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is an Adjunct Professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department.

TWST: Would you please tell us about Nutra Pharma?

Mr. Deitsch: Nutra Pharma (NPHC.OB), for want of a better term, is a biotechnology holding company. We seek out interesting concepts, drugs and devices in the biotechnology field, and we bring it into the Nutra Pharma family. We are especially good at finding diamonds in the rough - companies that are poorly managed and/or undercapitalized, and bring them competent management, qualified business plans and then necessary funding. Utilizing this strategy, we now have two divisions: ReceptoPharm is our drug discovery division and Designer Diagnostics is our medical device division. In ReceptoPharm we have drugs for the treatment of HIV, multiple sclerosis (MS), rheumatoid arthritis, adrenomyeloneuropathy (AMN) and pain. In Designer Diagnostics we have medical devices for the rapid isolation and detection of mycobacteria, which are bacteria that are very hard to culture and grow.

TWST: What does all of this translate into as far as an agenda for Nutra Pharma over the next year? What events should occur and what specific milestones will be reached?

Mr. Deitsch: We just announced the launch of our pain drug called Cobroxin. Cobroxin is the first over-the-counter drug for the treatment of chronic and persistent pain - in essence Stage II pain, which is normally treated with prescription medication, usually opioids or narcotics like Percocet and Vicodin. Here we have a drug that is safe, all natural and proven in more than 46 clinical studies to be able to treat chronic and persistent pain. Cobroxin will be on store shelves by the end of October, beginning of November of 2009, and we expect to see a national rollout across the country by January. What is exciting for us is our first substantial revenue stream from the sale of products. Additionally, we are going to launch a prescription version of Cobroxin in the first quarter of 2010 that will be for the treatment of Stage III pain. We expect the clinical research for that to be available early in 2010 and the product available in the first quarter of 2010. This does not mean that we have stopped our platform process with our other drugs. We are going to pursue our Phase II study in multiple sclerosis through 2010 and 2011. We expect to move into Phase III studies in 2010 for adrenomyeloneuropathy. We are also going to pursue our antiviral platform, looking at HIV and co-infected patients with other diseases along with HIV throughout 2010. It is going to be a really exciting year for ReceptoPharm, moving all of our drug products forward but having a nice solid revenue stream to finance everything. With Designer Diagnostics, we are seeking to acquire through licensure and acquisition some more medical devices to flesh out that division and then finish our validation of the Designer Diagnostics Test Kit at National Jewish Hospital in Denver.

TWST: Tell us about the management team, the science side, the development side and the business side, and what you might be looking to augment at this point as you progress as a company.

Mr. Deitsch: I am a biochemist and the CEO of the company. As far as management, I have the 30,000-foot view of everything. My background is in research and development for drugs from venom sources, working mostly with cone snails and then eventually with snake venom, like cobra venom. I also have successfully founded 16 different businesses, which is what allowed me to help fund Nutra Pharma during our development stage. Looking at ReceptoPharm, we have Dr. Paul Reid, a neurobiochemist with the background of working with the U.S. Army at Fort Detrick, which is where they do a lot of work in infectious diseases. He is considered one of the foremost experts on snake venom in the United States and probably in most of the world, and has a great understanding of the neurologic implications of the venom components. He has been conducting this work for almost 20 years. He is a recognized expert and we are very lucky to have him. He functions as the CEO of ReceptoPharm. Larry Raymond functions as the Chief Scientific Officer of ReceptoPharm. He created the monoclonal antibodies that allow for the research and standardization of our drug therapies. He has an amazing understanding of how the peptides interact and why, in fact, we do not get inhibitory antibody responses from the use of our drugs. We also have Neil Roth, who serves as the President of Designer Diagnostics. His background is in the pharmaceutical industry on the retail side in wholesale and distribution. His experience includes serving as the Senior Vice President for the Eckerd Corporation. Here we have somebody in place that can clearly move product from ideation and design into the marketplace. We also have a robust board of directors. The current board includes Dr. Paul Reid and myself. Additionally, we are very fortunate to have Dr. Stewart Lonky. Dr. Lonky is a triple board-certified medical doctor, internist, a pulmonologist and a thoracic surgeon. He is incredibly accomplished. He has one of the most thriving pulmonology practices in Los Angeles. He functions as one of our independent directors. He is also the founder of several medical device companies. He has an understanding of bringing products from ideation into the marketplace. Our newest board member is Garry Pottruck, who serves as the head of our audit and compensation committees. Garry is a CPA with decades of experience in public accountancy, and even functioned as the auditor and accountant for public companies. We are lucky to have him as an independent director on our board. We are planning to bring on a full-time Chief Financial Officer as well as a Chief Marketing Officer as we begin to realize revenues from the sale of Cobroxin. ReceptoPharm plans on hiring more hands to do tech work, research and light manufacturing.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 76 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

Buzz up!